| Company: | Moderna |
|---|---|
| CEO: |
|
| Founded: | 2010 |
| Symbol: | MRNA |
| Exchange: | NASDAQ |
| Industry: | Biotechnology |
| Sector: | Healthcare |
| About |
Moderna, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccineslude COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, human immunodeficiency virus, herpes simplex virus, and varicella-zoster virus vaccines; and public health vaccines consists of Zika and Nipah vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; localized regenerative, systemic intracellular, and inhaled pulmonary therapeutics. It has strategic alliances with AstraZeneca PLC; Merck & Co.; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Carisma Therapeutics; Metagenomi; the Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation, as well as a collaboration and license agreement with Chiesi Farmaceutici S.P.A. The company was formerly known as Moderna Therapeutics and changed its name to Moderna in August 2018. Moderna was founded in 2010 and is headquartered in Cambridge, Massachusetts. |
83 among 2804 companies
325 Binney Street
Cambridge | MA |
US
Moderna was founded on 2010, which makes the company 16 years old.
Stéphane Bancel is the CEO of Moderna.
Moderna operates in the Biotechnology industry and the Healthcare sector.
Moderna has 4,700 employees.
In fiscal year 2025, Moderna generated a revenue of $1.94 Billion.
In fiscal year 2025, Moderna reported a net income of -$2.82 Billion.
Product Sales is Moderna's biggest product segment, representing 100% of its total revenue.
Moderna went public on Dec 7, 2018, through its Initial Public Offering (IPO), and it has been 7 years since then.
Moderna's ticker symbol is MRNA, and the company is listed on the NASDAQ stock market exchange.
Moderna's current stock price is $47.07 as of Jun 9, 2026.
Ranked #83among 2,804 companies based on market cap.
Competitors of Moderna include Regeneron Pharmaceuticals, and more.